Effect of different doses of splenic polypeptide on cancer relative fatigue and quality of life in patients with advanced malignant tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033608

Enrollment

Unknown

Registered

2020-06-07

Start date

2020-07-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced malignancy

Interventions

A:Spleen polypeptide injection 4ml

B:Spleen polypeptide injection with 10ml

C:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with malignant tumors confirmed by histopathology and / or cytology; 2. Unable to surgical resection of the lesion; 3. One month before not be treated by radiotherapy and chemotherapy; 4. Aged 18 to 80 years; 5. The patient himself or his family members sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have severe acute infection and are not under control or have pyogenic and chronic infection wound migration; 2. The former serious heart diseases include high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease and stubborn hypertension which can not be controlled by congestive heart failure; 3. Mental illness; 4. Patients with abnormal coagulation and bleeding tendency; patients undergoing thrombolysis or anticoagulation; 5. Spleen polypeptide allergy.

Design outcomes

Primary

Measure	Time frame
cancer-related fatigue;Quality of Life;	—

Secondary

Measure	Time frame
T cell subsets;	—

Countries

China

Contacts

Public ContactDuan Fangfang

The 3rd People's Hospital of Zhengzhou

161367749@qq.com+86 13673369237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026